N/A
Completed N=132
Obstructive Sleep Apnea Endotypes and Impact on Phenotypes of People Living With HIV
Source: ClinicalTrials.gov NCT03575143 ↗Enrolled (actual)
132
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcomePrimary: Reaction Time Measured Using the Psychomotor Vigilance Task — 346; 353; 348 ms
Summary
The investigators seek to understand how the different underlying causes of OSA affect the way people living with HIV (PLWH) experience OSA. The investigators also want to understand how symptoms of obstructive sleep apnea improve with treatment, and if this too, is affected by the underlying cause of OSA in that individual
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Reaction Time Measured Using the Psychomotor Vigilance Task |
346; 353; 348 | — |
| SECONDARY Reactive Hyperemia Index (RHI) Assessed by Peripheral Arterial Tonometry |
1.6; 1.52 | — |
Eligibility Criteria
Inclusion Criteria
- Physician diagnosis of HIV and viral suppression
- Ages 18-65 years old
- BMI 20 - 35 kg/m2
Exclusion Criteria
- Pregnancy
- Inability to complete study procedures, such as questionnaires that are only available/validated in English.
- Known OSA already on effective therapy and adherent to treatment
- Other known untreated sleep fragmenting disorder, such as periodic limb movement disorder, or narcolepsy. We will NOT exclude based on insomnia, given that OSA and insomnia frequently exist together.
- Chronic lung disease requiring the use of supplemental oxygen, or with evidence of hypercapnia due to obstructive lung disease.
Data sourced from ClinicalTrials.gov (NCT03575143). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.